Traditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical studies has been studied using overall survival and more recently tumor-based end points such as progression-free survival, measurements of response to treatment. However, these seem not to be the relevant clinical end points in current situation if such end points were no validated as surrogate of overall survival to demonstrate the clinical efficacy. Appropriate, meaningful, primary patient-oriented and patient-reported end points that adequately measure the effects of new therapeutic interventions are then crucial for the advancement of clinical research in metastatic colorectal cancer to complement the results of tumor-based end points. Healthrelated quality of life (HRQoL) is effectively an evaluation of quality of life and its relationship with health over time. HRQoL includes the patient report at least of the way a disease or its treatment affects its physical, emotional and social well-being. Over the past few years, several phase III trials in a variety of solid cancers have assessed the incremental value of HRQoL in addition to the traditional end points of tumor response and survival results. HRQoL could provide not only complementary clinical data to the primary outcomes, but also more precise predictive and prognostic value. This end point is useful for both clinicians and patients in order to achieve the dogma of precision medicine. The present article examines the use of HRQoL in phase III metastatic colorectal cancer clinical trials, outlines the importance of HRQoL assessment methods, analysis, and results presentation. Moreover, it discusses the relevance of including HRQoL as a primary/co-primary end point to support the progression-free survival results and to assess efficacy of treatment in the advanced disease setting. 
Introduction
The choice of a primary end point reflecting the true clinical benefit to the patient is paramount in clinical phase III trial design. Although, overall survival (OS) has been considered as the most relevant end point, it is now widely recognized as challenging when several therapeutic lines are available [1] . Other tumorrelated outcomes such as progression-free survival (PFS) and response rate (RR) in the metastatic setting and disease-free survival (DFS) or recurrence-free survival in the adjuvant setting have been used [2] . These tumor-related end points, however, are not necessarily validated surrogates for OS nor do they translate into significant improvements in the duration and/or quality of survival. In this context, the value of several new therapeutic treatments has been called into question. Some interventions that provide only a marginal benefit as judged by extension of PFS, for example, might not be of sufficient value to patients, specifically those with advanced-stage cancer.
Over the past four decades, health-related quality of life (HRQoL) has been integrated into phase III clinical trials, including metastatic colorectal cancer (mCRC) studies, as important clinically relevant patient-reported outcome (PRO). PROs, including HRQoL, symptoms, treatment preferences, and patient satisfaction reflect patient subjective disease evaluation and treatment effect on patient daily life. HRQoL has been found a key indicator of patient treatment efficacy and safety by meta-analysis [3] [4] [5] [6] [7] . Better QoL physical function and global QoL score were independent predictors of longer OS, while better cognitive QoL was predictive of less adverse events in patients with pancreatic cancer [8] .
Despite the above-mentioned findings and the fact that the US Food and Drug Administration (FDA) recognized HRQoL as a component end point for cancer therapy approvals [9] , HRQoL is frequently neither adequately captured in clinical trials of advanced CRC (inaccurately applied, used as secondary/tertiary end point, estimated in post hoc analysis) nor translated (or rarely) into clinical decision-making.
We outline a potential added value of HRQoL in the advanced CRC setting and discuss selected examples of phase III CRC trials that highlight the relevance of including HRQoL as a primary/ co-primary measure of new therapeutic interventions. The methodological quality of HRQoL assessment, analysis, and presentation are also discussed.
Status of HRQoL
In mCRC clinical phase III trials, OS has been considered the optimal measure of treatment benefit due to its objectivity and accuracy. However, it requires a long-term follow-up and a large number of patients to show statistically significant differences between treatments. Therefore, PFS is used as surrogate for OS, particularly in studies evaluating novel cancer therapies targeting a molecularly defined specific subpopulation of patients. Unlike OS, PFS is subjected to inherent biases and to measurement error. In addition, PFS may not reflect a true clinical benefit and it may not always be clinically relevant, especially when marginal treatment effects do not translate into OS increase. Large differences in PFS between the trials arms may then be required in order to consider it as relevant indicator of efficacy. Surrogacy of PFS for OS with fluoropyrimidines alone is weaker with currently available lines of treatment based on new drugs and targeted therapies [1] . Interestingly, the results of a survey conducted among clinicians and methodologists involved in the conduct of digestive cancer trials showed that in mCRC, PFS (75%), QoL together with PFS and R0 metastatic resection rate (56% both) were considered the 'optimal' alternative end points of OS in the metastatic setting [10] . Association between PFS and HRQoL was found in CRC patients treated with panitumumab [11] . Siena et al. [11] reported that a lack of disease progression at week 8 was associated with significantly and clinically meaningful lower CRC symptomatology [National Comprehensive Cancer Network (NCCN)/Functional Assessment of Cancer Therapy (FACT) CRC symptom index (FCSI)] and HRQoL [EuroQol-5D (EQ-5D)] for panitumumab and best supportive care patients and higher HRQoL for panitumumab patients only. However, this study was carried out in pre-treated patients who had failed on all available therapies at that time, a setting where symptoms are frequent and HRQoL is often already impaired at the time of study enrollment, which is usually not the case in mCRC when metastasis are first diagnosed. In earlier disease stages, showing that a new drug that improves PFS did not compromise HRQoL, reinforce the survival results and influence the assessment value of the intervention [12] .
Given the above findings, any increase in survival, specifically in PFS only without an OS benefit, should be accompanied by a gain and/or an improved or maintained HRQoL if it is to be considered clinically relevant [13, 14] . Therefore, we propose the HRQoL assessment alongside with PFS and other potential end points in order to acquire a clinically reliable net value. HRQoL could also have a greater significance with intermittent therapy, in which PFS in its purest form is probably unhelpful and HRQoL is likely improved. In the palliative setting for mCRC, a goal of strategies with recent FDA approved agents that show small relative OS benefit, would be to maintain HRQoL instead of prolonging OS.
Assessment of HRQoL
HRQoL is commonly assessed using patient-reported questionnaires. A wide range of generic and cancer-specific modules to its measure have been developed and refined in the last years. The EORTC QOL Core Questionnaire (EORTC QOL-C30) [15] , the Functional Assessment of Cancer Therapy-General (FACT-G) [16] , the 36-item short-form health survey (SF-36) [17] , and the EuroQoL-5D [18] are the most widely used.
Colorectal cancer and its treatments may adversely affect different dimensions of HRQoL, especially physical (e.g. social limitations as a result of physical health, pain/discomfort, general health perception), social (e.g. distress management, inability to socialize), economic (e.g. transportation/medical costs, missed employment), emotional (e.g. anxiety, depression, low self-esteem), family (e.g. inability to provide appropriate support), and medical aspects (e.g. diarrhea, fatigue, impaired body image, sexual problems). These factors may affect treatment decisions, keeping medical appointments, following the recommended regimen/recommended medications/nutrition, or reporting adverse events or other factors to providers. Therefore, the choice of a tool to assess HRQoL is important in trials for advanced cancer to capture potential and relevant facts about the short and long-term impacts/effects of treatment and the cancer.
The FACT-C (discriminates colon vs. rectal patients) consisting of the 28-item FACT-G and the 9-item colon subscale is the most commonly used CRC specific questionnaire, validated in many countries [19] [20] [21] [22] [23] . Two specific modules, the EORTC QLQ-CR29 [24] and the liver metastasis EORTC QLQ-LMC21 [25] , were designed for use with the EORTC QLQ-C30 in CRC. Few data are available in the literature on the responsiveness of these questionnaires to change (e.g. the spread of cancer, chemotherapy outcomes) [22, 26] . The EORTC QLQ-CR29 is psychometrically validated in colon and rectal cancer patients at various stages of their treatment that covers physical, psychosocial, and CRC-specific symptom-oriented questions. This questionnaire has sufficient validity and reliability to supplement the EORTC QLQ-C30 [24] . The validated EORTC QLQ-LMC21, covers symptom and function items specific to patients with CRC liver metastases and measures activity problems, abdominal pain, nutritional problems, and emotional function [25] . The low anterior resection score (LARS) is a five-item questionnaire for evaluation of HRQoL in patients following surgery for rectal cancer. Validation of the LARS score is in progress [27] .
Some instruments such as the National Institute of Health's (NIH) Patient-Reported Outcome Measurement Information System (PROMIS) were developed to be applicable across diseases and not to be used as cancer-specific tool [28, 29] . PROMIS, with standardized PRO measures referenced to the US general population, covers both generic and more specific items (e.g. sexual function). It integrates the use of item response theory and computer adaptive testing to create individualized questionnaires [28, 29] . The PROMIS relative performance psychometrics and, its prognostic nature for OS, DFS, and time to progression as well as the PRO-Common Toxicity Criteria measures versus simple a single-item numerical analogue scale assessment in the context of clinical studies have been investigated in the USA to facilitate adoption by clinical researchers.
HRQoL analysis and interpretation
Efficient, reliable, and clinically meaningful HRQoL assessment in the clinical and routine clinical practice setting is not without specific limitations and challenges. Several difficulties such as the utility and availability of HRQoL instruments, methodological concerns (e.g. validity/reliability of measures) and logistic/practical considerations (e.g. feasibility of tools, scoring, interpretation) are encountered. HRQoL questionnaires are often lengthy, not easily understandable, and with complex scoring algorithm making their administration for routine use overdue and difficult. Implementation of in-clinic information technology (e.g. computer tablets) for data collection could facilitate this process. Basch et al. showed that systematic web-based reporting of patient-reported symptoms with automated clinician e-mail alerts resulted in better HRQoL, fewer emergency room visits, fewer hospitalizations, a longer duration of palliative chemotherapy, OS, and quality-adjusted survival in patients treated with chemotherapy for metastatic breast, genitourinary, gynecologic, or lung cancers [30] .
Given the longitudinal nature of HRQoL studies, identification of the appropriate time-points for clinically meaningful changes is also challenging. In addition, differences in the HRQoL definition perception, non-standardized and inconsistent use of multiple instruments, and differences in reporting make a cross-study comparison difficult. Moreover, the HRQoL results interpretation can be problematic due to missing data and the patient dropout (health status deterioration, progression/relapse, death) [31] . Patient response-shifts over time further complicate the HRQoL data interpretation [32] .
Another challenging aspect is HRQoL longitudinal data analysis that remains largely unstandardized often due to a lack of uniform approaches. Moreover, this analysis frequently produces clinically insignificant results. Although several methods to analyze longitudinal HRQoL data are available, these are rarely used by the health professionals mainly due to their complexity. It was well highlighted by the AVAglio [33] and RTOG 0825 [34] trials evaluating the addition of bevacizumab to radiotherapy in glioblastoma patients. While PFS was significantly different in favor of bevacizumab, no OS benefits were observed in either trial. However, HRQoL results were conflicting. In RTOG 0825, HRQoL was lower among bevacizumab-treated patients, while in AVAglio, the time to HRQoL score deterioration was longer in the bevacizumab group.
Hamidou et al., used time until definitive deterioration (TUDD) statistical approach [35, 36] in the analysis of patients with mCRC and showed that time to deterioration in HRQoL did not differ significantly according to type of treatment. TUDD produces meaningful longitudinal HRQoL results easily interpreted by clinicians and thus improving clinical decision-making.
HRQoL relationship to OS Prognostic value
HRQoL, besides being an important end point in clinical trials, is also an independent predictor of OS and, to some extent, of the patient response to treatment (marker of disease progression) [4, 37, 38] . Gotay et al. [4] reported that in 36 of the 39 analyzed studies PROs were significant predictors of survival, often a more accurate predictor than ECOG performance status. Several studies have demonstrated that baseline HRQoL is associated with OS duration in CRC. In a pooled analysis from four randomized trials by Maisey et al. [37] , better baseline global HRQoL scores (up to few months after treatment) were independently associated with longer survival in mCRC patients (>1 year). The authors recommended routine HRQoL measurements for stratification and comparison of outcomes in different cohorts of patients. In two other studies by Braun et al. [38] and Efficace et al. [39] , a 10-point increase on the social functioning scale or in baseline global HRQoL score was associated with a 7% and 6% decrease in the patient's hazard of death, respectively. Some authors showed that at least one HRQoL domain supplements prognostic information in addition to clinical and socio-demographic variables (WHO performance status, distant metastases, age, sex, and clinical factors) [40, 41] . Baseline physical functioning score was independently associated with OS in study of mCRC patients treated with oxaliplatin-based first-line chemotherapy [42] , while self-reported HRQoL was not a significant prognostic factor for CRC recurrence in other study [43] . In addition, in a trial of CRC patients with liver metastases, HRQoL offered more accurate prognostic information for OS than the number/volume of metastases [44] .
Effect of treatment on HRQoL
Introduction of biologic agents into mCRC first-line treatment has resulted in increased RRs, PFS, and OS [45] [46] [47] [48] [49] [50] [51] . Many of these therapies are combined with cytotoxic regimens (e.g. capecitabine, irinotecan, oxaliplatin) and thus may have a significant impact on the patients' HRQoL.
In patients with surgically unresectable metastatic disease, chemotherapy, given its modest influence on OS, is usually administered with palliative intent. Although the goal of palliative therapy is the quality of survival, the impact of anticancer treatment has been evaluated by the length of survival and toxicity. The main goal of chemotherapy, however, is to be delay HRQoL deterioration by reduction of the severity of disease-related symptoms.
A treatment can be chosen if it significantly improves HRQoL and well-being of the patient without significant OS benefit versus comparable treatment. In the phase III COIN trial [51] intermittent chemotherapy was non-inferior to continuous treatment in terms of OS. However, subgroup analysis demonstrated that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in OS, are likely to experience fewer side-effects, and have improved HRQoL; those with increased platelet levels seem to do significantly worse on intermittent treatment and should not receive treatment breaks.
A treatment may not be optional if symptoms and HRQoL remain similar to that under the comparable treatment, without significant OS improvement. The NORDIC-VII phase III study of mCRC treated with cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) or FLOX alone in did not show any OS, PFS, and QoL benefit with the addition of the biologic, even in patients who were deemed KRAS wild-type [52] .
Clear treatment decisions seem challenging when treatment offers better chances of survival, but with impaired HRQoL compared with conservative therapy or lower changes of OS, but improved HRQoL. In such cases, if the primary end points are not met, HRQoL outcomes are critical to decision whether combination therapy is beneficial from the patients' perspective. These examples show how HRQoL could potentially guide therapy in the future if appropriately integrated into studies.
Also it might be the right time to consider HRQoL for prognostic scores to optimize any therapeutic strategy efficacy and to consider the effects of a treatment strategy on HRQoL end point in order to be in line with a dogma of precision/personalized medicine.
Minimal clinically important difference
With the expanded use of HRQoL end point and the increasing number of HRQoL instruments, it is necessary to interpret HRQoL in the context of minimal clinically important difference (MCID) improvements. MCID defines the smallest change in HRQoL, going beyond statistical significance, beneficial from patients' perspective, and leading to a change of the patient care [53] . Anchor-based (HRQoL scores are correlated with another independent measure) and distribution-based (measure of variability/distribution of results) methods are used to capture MCIDs.
There is a body of the literature regarding the clinical significance of changes in different questionnaires. In the EORTC QLQ-C30, a 5-10 mean score difference is regarded as a small, but subjectively significant or clinically meaningful, a 10-20 point change is regarded as moderate, and a >20-point change as large [54] [55] [56] . Regarding CRC-specific questionnaires, Yost et al. [57] identified MCID scores as: 1-2 points for the Colorectal Cancer Subscale (CCS) specific, 4-6 points for the Treatment Outcome Index colorectal, and 5-8 points for the FACT-C total. For the FCSI (sensitive to symptomatic progression in metastatic patients), the MCID was defined as a change in the range of 1.5-3.0 points [58] .
Response evaluation criteria in solid tumors criteria and HRQoL
Response evaluation criteria in solid tumors (RECIST) criteria for HRQoL can be helpful to characterize deterioration/improvement of and the magnitude of change in HRQoL parameters that have clinically meaningful effects. Moreover, these can help to reach standardized longitudinal HRQoL analysis using the TUDD method. With the objective of OS and HRQoL improvement, as for tumor response and progression, RECIST criteria for HRQoL should be defined and integrated into trial design. Development and validation of RECIST criteria for HRQoL in mCRC will be addressed by the international ARCAD (Aide et Recherche en Cancerologie Digestive) group in the near future [59] [60] [61] . An ongoing project granted by the EORTC QOL group would be also done for all cancer localizations.
HRQoL in mCRC phase III clinical trials
We have identified 31 pivotal first and second-line randomized phase III clinical trials on anticancer therapies for mCRC with HRQoL end point (supplementary Table S1 , available at Annals of Oncology online) [11, 40, 45, [48] [49] [50] [51] [52] . To pinpoint those trials we conducted a literature review including a PubMed search using the search terms 'QoL', 'end point', 'phase III', 'colorectal', 'first/second-line 'and 'randomized'; and an abstracts search from conference (ASCO, ASCO GI, ESMO) proceedings. Studies included mostly first-line therapy trials (n ¼ 29; 93.5%). The majority of trials used HRQoL as pre-specified secondary end point (93.5%), except for two studies, in which HRQoL was adapted as a co-primary (alongside PFS) or tertiary objective. These observation points out that although the importance of HRQoL assessment in clinical trials is now generally accepted, many clinicians are still skeptical about its true additive value when testing different therapeutic strategies and are hesitant to accept HRQoL as a primary/co-primary end point. Furthermore, HRQoL data were presented separately for eight trials (25.8%). Although splitting up HRQoL data from survival results seems to be opportunity for a comprehensive way of reporting, such action has also certain disadvantages. Separate reporting of survival and HRQoL results may reduce their value in clinical decisionmaking as clinicians are unlikely to read or are not aware of the successive paper published following the main results [101, 102] . It is therefore recommended that clinical and HRQoL sets of data are published in the same manuscript in order to provide more complete account of outcomes and in turns optimal therapeutic strategies in patients with advanced disease. Another alternative could be to publish a companion paper in the same journal at the same time, as reflected by the published results from the AURELIA phase III study of bevacizumab in ovarian cancer [103, 104] .
Although different measures were used to assess HRQoL in the selected studies, consistent use of the generic questionnaires was observed: EORTC QLQ-C30 (22/31; 71.0%), EQ-5D (7/31; 22.6%), and SF-36 (2/31; 6.4%). However, only 8 of 31 reviewed trials (25.8%) used CRC-specific questionnaires (of which four used FACT-C, two used FACT-FCSI, one used EORTC QLQ-CR29, two used CCS, and one used TOI-C; supplementary Table  S1 , available at Annals of Oncology online) [11, 40, 45, [48] [49] [50] [51] [52] . These were used either alone or in association with generic questionnaires. While the generic HRQoL questionnaires are well-validated and robust measures, they do not cover specific mCRC-related aspects and therefore may miss effects of new therapies on patients' HRQoL. It is hence vital to use CRCsensitive/discriminate questionnaires (and score them along with generic instruments) in mCRC patients.
HRQoL data quality may be diminished by poor compliance in questionnaire completion as the study progress. Quinten et al. [40] showed that patients who did not complete the questionnaires may have poorer survival. A generation gap between patients (the average age of mCRC patients is 65 years) may also contribute to HRQoL data non-compliance given different approaches of capturing HRQoL (e.g. telephone, electronic, paper). Only 14 of 31 reviewed trials (45.2%) reported patient compliance for HRQoL questionnaires completion (supplementary Table S2 , available at Annals of Oncology online) [11, 40, 48-51, 62, 63, 70, 75, 77-82, 84, 86, 94, 95, 100] . Four trials (28.6%) provided the total number of patients who completed the questionnaire at baseline, while three of these did not specify compliance rates during the trial. In all trials, the baseline compliance rates ranged from 84% to 98%. As expected, the post-baseline decline in completing questionnaires was observed. Moreover, differences in reporting missing data (not sufficient/no data at all) and longitudinal analysis were observed across the retrieved studies. Missing data at later time points may be related to treatmentrelated toxicities, tumor progression, difficulties in completing questionnaires, or low stress on HRQoL measure. This aspect can introduce bias selection (toward worse or better HRQoL), reduction in statistical power to detect MCID (reduced number of observations), and finally lead to misleading results regarding HRQoL, which is particularly relevant in patients with advanced and progressive disease.
We also investigated the relationships between survival, tolerance, and the HRQoL scores (Table 1 ) across the reviewed trials. A significant difference between arms with regard to HRQoL was found in 16 out of 31 trials (51.6%), eight and five of which had PFS and OS as the primary end point, respectively, one had OS and DFS as the co-primary end points, one had OS and PFS as the coprimary end points, and one had time to failure strategy as the primary end point. Six of 15 trials (40%) and 8 of 14 trials (57.1%) that demonstrated or did not show OS or PFS benefit, respectively, and two trials (100%) with OS negative results found significant differences in QoL scores. These observations are of importance as demonstrate that 50% of trials that did now show survival differences demonstrated significant HRQoL changes. Moreover, in only one trial [86] , the improved survival came at a cost of decreased HRQoL. Although greater tolerance was seen, generally it did not have any adverse impact on neither survival nor HRQoL.
Longitudinal HRQoL studies can reveal insight into changes in HRQoL scores as patients undergo treatment. Despite many sophisticated statistical approaches available, longitudinal analysis of HRQoL remains generally unstandardized and inconsistent, which can compromise the results between trials. Our assessment revealed remarkable across-trials longitudinal analysis heterogeneity. Although longitudinal designs were widely adopted, advanced statistical methods were commonly underutilized. The majority of studies were analyzed using traditional methods that account for repeated measures (20/30; 66.7%), such as pattern-mixture model, linear-mixed model, Wei-Lachin or Wilcoxon rank-sum tests. Only four of 30 studies (13.3%) implemented time-to-QoL deterioration (TTD), and only four used mixed-effect model for repeated measures approach. In six studies (20%) the statistical strategies were not at all reported (supplementary Table S1 , available at Annals of Oncology online) [11, 40, 45, [48] [49] [50] [51] [52] . In addition, missing data was rarely discussed.
Suggestions for future mCRC trials
Considering the above, we propose the following for future mCRC clinical trials:
1. HRQoL should be strongly considered as a co-primary end point alongside a tumor-based parameters such as PFS in the first-line and later settings [60, 105] . Appropriate investment and strategies to ensure completion of data collection and minimization of drop out is critical. 2. HRQoL could be used as a composite end point with tumor parameters when: treatment effects on each component of end point is expected to be of similar efficacy, treatment is expected to have long-term negative effects on patients HRQoL, and treatment effects are estimated to be small, but clinically meaningful. This approach would ensure adequate sample size for meaningful HRQoL assessments. 3. Specific instruments such as the EORTC QLQ-C30 form associated with the EORTC QLQ-CR29 form should be used to increase the sensitivity for HRQoL changes detection and to compare between studies along with more general tools. 4. The specific HRQOL dimensions should be targeted to prevent multiple testing and inflation of type one error with associated decisions rules regarding the conclusion of the trial. Mandatory dimensions should include: global health status (true overall impact assessment of disease and its treatment on the patient, assessment of at least one dimension comparable across trials, impact measurement of other dimensions on global health), functional scales, symptoms scales (measurement of ongoing treatment and/or on treatment with late toxicity effects), and CRC-specific dimensions of the QLQ-CR 29 (capturing sensibility to change).
Complementary dimensions could be targeted for exploratory purposes only. With HRQoL as a co-primary end point, complementary dimensions could be considered as secondary end points for confirmatory purposes. 5. Timing driven design should be preferred for collection of HRQoL data. Assessment times of HRQoL should coincide with the clinical care schedule dictated by the trial regimens, but it is essential to measure it at baseline (before randomization), at least every month until death for trials with an expected median OS 1 year, at least every month during treatment, and at least every 2-3 months until death for trials with an expected median OS > 1 year. For strategy trials, follow-up should be measured until death or at least treatment failure of the last chemotherapy line evaluated. 6. HRQoL should be an integrated component of prognostic scores (e.g. the GERCOR prognostic score) [106] and considered as a stratification factor in mCRC clinical trials.
Conclusion
Based on an extensive literature review and the experts opinions, we propose guidelines for the development of parameters that will facilitate the conduct of future mCRC clinical trials with HRQoL as a co-primary/composite end point and will ensure their methodological and analytical quality and comparability. 'Better clinical efficacy' considered when a significant improvement was reported in primary end point. 'Same clinical efficacy' indicates not significant results. Different indicates trials in which no global QoL differences were found, but the assessment of specific symptoms favored one or more of the arms.
